ConvaTec Group (LON:CTEC) Given New GBX 340 Price Target at Berenberg Bank

ConvaTec Group (LON:CTEC) had its price target hoisted by analysts at Berenberg Bank from GBX 330 to GBX 340 in a research report issued on Thursday,Digital Look reports. The firm currently has a “buy” rating on the stock. Berenberg Bank’s target price would indicate a potential upside of 43.70% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Peel Hunt reissued an “add” rating and issued a GBX 270 price target on shares of ConvaTec Group in a research note on Thursday, November 13th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th. Finally, UBS Group reissued a “buy” rating and set a GBX 375 target price on shares of ConvaTec Group in a research note on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, ConvaTec Group currently has a consensus rating of “Buy” and an average price target of GBX 320.33.

ConvaTec Group Stock Performance

Shares of CTEC stock opened at GBX 236.60 on Thursday. The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. ConvaTec Group has a twelve month low of GBX 219.80 and a twelve month high of GBX 311.20. The company’s 50-day moving average price is GBX 236.36 and its 200-day moving average price is GBX 237.98. The stock has a market cap of £4.61 billion, a price-to-earnings ratio of 22.32, a PEG ratio of 0.93 and a beta of 0.64.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.